Dipartimento di Scienze Chirurgiche, Università degli studi di Torino, Torino, Italy.
Epidemiologia Clinica e Valutativa, AOU Città della Salute e della Scienza di Torino e CPO Piemonte, Torino, Italy.
J Clin Oncol. 2022 Nov 20;40(33):3817-3827. doi: 10.1200/JCO.22.00471. Epub 2022 Jul 20.
In the absence of clear evidence from randomized trials, the intensity of follow-up regimens after surgical treatment of endometrial cancer is highly variable in clinical practice. To reduce this uncertainty, we conducted a randomized trial to test whether an intensive (INT) versus a minimalist (MIN) follow-up regimen improves overall survival (OS) in patients undergoing operation for endometrial cancer.
The TOTEM study was a large, pragmatic randomized trial, conducted in 42 hospitals (in Italy and France) including patients surgically treated for endometrial cancer, in complete clinical remission, International Federation of Gynecology and Obstetrics stage I-IV. After stratification by center and risk of relapse (low or high), patients were randomly assigned (1:1) to INT or MIN hospital-based follow-up regimens. The study was powered to demonstrate an absolute improvement of 5% of the 5-year OS with the INT regimen.
In total, 1,871 patients were randomly assigned between November 2008 and July 2018, and 1,847 patients (98.7%) were available for the final analysis (60% low risk). After a median follow-up of 69 months, the 5-year OS was 90.6% in the INT and 91.9% in the MIN arms (hazard ratio, 1.13, 95% CI, 0.86 to 1.50, = .380). No differences in OS were found in subgroup analyses considering age, cancer treatment, risk of relapse, and degree of adherence of the center to the scheduled follow-up. The probability of detecting a relapse was slightly higher in the INT arm (hazard ratio, 1.17; 95% CI, 0.92 to 1.48; = .194).
An INT follow-up in endometrial cancer-treated patients does not improve OS, even in high-risk patients. According to available evidence, there is no need to routinely add vaginal cytology, laboratory, or imaging investigations to the MIN regimens used in this trial.
在缺乏随机试验明确证据的情况下,子宫内膜癌手术后的随访方案强度在临床实践中存在很大差异。为了减少这种不确定性,我们进行了一项随机试验,以测试强化(INT)与简化(MIN)随访方案是否能改善接受子宫内膜癌手术治疗的患者的总生存(OS)。
TOTEM 研究是一项大型、实用的随机试验,在 42 家医院(意大利和法国)进行,纳入了国际妇产科联合会(FIGO)分期 I-IV 期、完全临床缓解的子宫内膜癌手术治疗患者。根据中心和复发风险(低或高)分层后,患者以 1:1 的比例随机分配到 INT 或 MIN 医院随访方案。该研究的目的是证明 INT 方案可使 5 年 OS 绝对提高 5%。
2008 年 11 月至 2018 年 7 月期间,共随机分配了 1871 名患者,最终有 1847 名(98.7%)患者可进行最终分析(低风险占 60%)。中位随访 69 个月后,INT 组和 MIN 组的 5 年 OS 分别为 90.6%和 91.9%(风险比,1.13,95%CI,0.86 至 1.50, =.380)。考虑年龄、癌症治疗、复发风险以及中心对预定随访的依从性,亚组分析未发现 OS 差异。INT 组检测到复发的概率略高(风险比,1.17;95%CI,0.92 至 1.48; =.194)。
在子宫内膜癌治疗患者中,强化随访并不能提高 OS,即使是高危患者也是如此。根据现有证据,没有必要在本试验中使用的 MIN 方案基础上常规添加阴道细胞学、实验室或影像学检查。